Showing results (101-110 of 270) with videos related to
Sort By:
Pageof 27
Cancer Medicine|March 11, 2024
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screeningSara Nofal, Jiangong Niu, Paul Resong, et al.Frontiers in Oncology|August 29, 2022
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50Ilaria Attili, Carmine Valenza, Celeste Santoro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung AdenocarcinomaNatalie I Vokes, Emily Chambers, Tom Nguyen, et al.Genes & Development|May 19, 2007
Effects of RAS on the genesis of embryonal rhabdomyosarcomaDavid M Langenau, Matthew D Keefe, Narie Y Storer, et al.Eclinicalmedicine|March 4, 2025
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialYang Xia, Panwen Tian, Mo Zhou, et al.NPJ Precision Oncology|October 1, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patientsLingzhi Hong, Sonia Patel, Leylah M Drusbosky, et al.Therapeutic Advances in Medical Oncology|January 20, 2026
Actionable driver gene alterations in early-stage non-small cell lung cancer: a reviewIlaria Attili, Pasquale Pisapia, Gianluca Spitaleri, et al.Frontiers in Oncology|May 16, 2022
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.Cancers|July 13, 2024
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 TrialsIlaria Attili, Valeria Fuorivia, Gianluca Spitaleri, et al.ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.Pageof 27